iiinova — where your digital self keeps evolving

Andrew Stern @andrewmstern.bsky.social · 01/10/2026

If fibril structure is faithfully transmitted through the brain, I see this as further evidence for true amyloid fibrils (PHF, etc), and against “non-fibrillar HMW oligomers,” as being the relevant seeding species. @sjorsscheres.bsky.social www.nature.com/articles/s41...

nature.com

Prion-like transmission of human tau strains in the mouse brain - Nature

Mouse experiments show that Alzheimer’s disease and corticobasal degeneration tau filaments retain their distinct structures during templated seeding, supporting strain-specific tau propagation a...

210

Andrew Stern @andrewmstern.bsky.social · 21/07/2026

My lab is looking for a new technician and/or postdoctoral fellow to join us! Many exciting projects on the molecular biology of amyloid beta and TDP-43. Please message or email.

010

Andrew Stern @andrewmstern.bsky.social · 10/06/2026

Encouraged to see that the FY27 LHHS appropriations bill emerged from House subcommittee with a ~3% increase in NIH funding compared to FY26. But this needs to be more like 20% to make up for a decade of stagnation.

010

Andrew Stern @andrewmstern.bsky.social · 06/06/2026

We found that Aβ fibrils at plaque edges form a complex with the U1 snRNP. U1-70k is the most-correlated insoluble protein with Aβ in AD. Previously thought to be intracellular in tangles, but we find it’s directly bound to Aβ. With @raflynn5.bsky.social. www.biorxiv.org/content/10.6...

biorxiv.org

053

Andrew Stern @andrewmstern.bsky.social · 15/04/2026

We were unable to find support for the claim that lecanemab binds a different, more soluble, human target than aducanumab and donanemab. Antibody preference for plaques vs CAA is unlikely to explain differences in ARIA-E rates. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

alz-journals.onlinelibrary.wiley.com

Anti‐amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain

INTRODUCTION Lecanemab binds “protofibrils,” which are poorly characterized in human brain. It is unknown why lecanemab caused fewer amyloid-related imaging abnormalities (ARIAs) than other antibodi.....

000

Reposted by Andrew Stern

Oded Rechavi @odedrechavi.bsky.social · 30/03/2026

Do we grow wiser as we age? I spent 15+ years chasing glam journals, wasting time and energy (and frustrating my team and co-authors). I don’t want to wake up at 70 and realize my life went into convincing a few editors my work was trendy enough. Enough. I’ll try to be smarter.

1516719

Andrew Stern @andrewmstern.bsky.social · 27/03/2026

My favorite NIH entity is the Council of Councils, which sounds like it might launch a war to defend Naboo.

020

Andrew Stern @andrewmstern.bsky.social · 18/01/2026

Knowing little about this, I’d ask how complex matrix C (the FC map) is - how many baseline circuits and regions there are. If it’s only a few highly connected regions in few circuits (eg the DMN), then I see their point. If the # of circuits >> # patients and lesions, then LNM should be valid?

010

Reposted by Andrew Stern

Talia Lerner @talialerner.bsky.social · 24/12/2025

Updating this graph for the holidays 🎁 (datapoints are a selection of journals publishing in neuroscience)

Graph titled "Paying for Impact 2025" showing Article Processing Charge (APC) vs Impact Factor for a selection of top journals in neuroscience - linear trendline R^2=0.636

0123

Andrew Stern @andrewmstern.bsky.social · 24/12/2025

Introducing Nature Baubles, the latest addition to Nature Portfolio. open.substack.com/pub/andrewms...

open.substack.com

Introducing Nature Baubles

Science has changed.

020

Andrew Stern @andrewmstern.bsky.social · 03/12/2025

Hi Usha, I would be happy to discuss the misinformed narrative about the Alzheimer’s field Piller is pushing. And perhaps you or he can explain why my ongoing work and that of thousands of others is part of a “Devastating Legacy of Lies.”

010

Reposted by Andrew Stern

Rémi Fronzes @fronzeslab.bsky.social · 30/11/2025

I fully agree. The term LLPS is probably not the correct one to describe what happens in cells. However, the formation of dynamic low-order condensates driven by low affinity multivalent proteins (often highly disordered) seems to occur in cells.

192

Andrew Stern @andrewmstern.bsky.social · 16/11/2025

If not LLPS, what term would you use to describe these quick off-rate polyvalent structures that show rapid FRAP recovery, droplet-mixing, etc? QuORPS?

220

Andrew Stern @andrewmstern.bsky.social · 16/11/2025

Well I see the appeal of using “liquid” as a term to describe a collection of polyvalent interactors, sliding along one another through rapid associations and dissociations. What would be a better term for this, distinct from aggregates with irreversible monovalent (oligovalent?) interactions?

120

Andrew Stern @andrewmstern.bsky.social · 16/11/2025

Do you think it better to describe condensates as concentrations of disordered macromolecules with specific but polyvalent interactions and quick off-rates?

130

Andrew Stern @andrewmstern.bsky.social · 31/10/2025

Any cryoEM folks know what these strange zebra-stripe particles are in a prep from human brain?

140

Andrew Stern @andrewmstern.bsky.social · 24/10/2025

We are looking to hire a postdoc to take this and other TDP-43 assay development forward! Please re-post!

131

Reposted by Andrew Stern

Young-Pearse Lab @typlab.bsky.social · 15/10/2025

Our study “Genetic and proteomic analysis identifies BAG3 as an amyloid‑responsive regulator of neuronal proteostasis" was published in Acta Neuropathologica this week! Congratulations to lead author Zach Augur, who will be defending his thesis later this week!! link.springer.com/epdf/10.1007...

link.springer.com

Genetic and proteomic analysis identifies BAG3 as an amyloid-responsive regulator of neuronal proteostasis

043

Reposted by Andrew Stern

Andrew Stern @andrewmstern.bsky.social · 25/07/2025

My lab is hiring a postdoc to work on new TDP-43 biomarkers! Please get in touch and re-post!

078

Andrew Stern @andrewmstern.bsky.social · 07/08/2025

BREAKING: Field makes inchwise progress over decades on intractable problem of dementia with interesting leads and blind alleys but smart people are doing their best and please don’t overinterpret their results because it takes a long time for a real breakthrough www.bostonglobe.com/2025/08/06/m...

bostonglobe.com

New hope for Alzheimer’s: Groundbreaking Harvard study finds lithium reverses brain aging - The Boston Globe

The research suggests a new approach to preventing and treating the mind-robbing disease.

030

Reposted by Andrew Stern

Jeremy Berg @jeremymberg.bsky.social · 31/07/2025

First highlight... Senator Capito started of the discussion saying that the bill contains AN INCREASE for NIH. The details are not available, but the bill will be released ofter the hearing. This is not a done-deal, but it does show where the Senate is on a bipartisan basis.

media.tenor.com

a cartoon of snoopy on a green background with the words `` great news ! ''

ALT: a cartoon of snoopy on a green background with the words `` great news ! ''

211929

Andrew Stern @andrewmstern.bsky.social · 25/07/2025

My lab is hiring a postdoc to work on new TDP-43 biomarkers! Please get in touch and re-post!

078

Andrew Stern @andrewmstern.bsky.social · 22/05/2025

Thanks guys. To be clear, I still favor that antibody directly binding to CAA could be a cause of ARIA. We just found that the difference in ARIA-E between lec and adu can’t be fully explained by differences in CAA preference.

130

Andrew Stern @andrewmstern.bsky.social · 22/05/2025

We studied the binding of clinical antibodies to human brain extracts and found no evidence that lecanemab binds a more soluble population of Abeta than aducanumab or donanemab, nor that binding preferences to CAA vs plaque explained different ARIA rates. www.biorxiv.org/content/10.1...

biorxiv.org

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain

Importance: Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/ede...

010

Reposted by Andrew Stern

alexlish.bsky.social @alexlish.bsky.social · 30/04/2025

Thrilled to share my first first-author paper is out @cp-neuron.bsky.social! We show that Alzheimer's disease protective CLU alleles upregulate CLU in response to neuropathology, dampening inflammatory signaling between microglia and astrocytes. Read here www.sciencedirect.com/science/arti...

sciencedirect.com

CLU alleviates Alzheimer’s disease-relevant processes by modulating astrocyte reactivity and microglia-dependent synaptic density

Genetic studies implicate clusterin (CLU) in the pathogenesis of Alzheimer’s disease (AD), yet its precise molecular impact remains unclear. Through u…

13519

Reposted by Andrew Stern

Young-Pearse Lab @typlab.bsky.social · 12/04/2025

Congratulations our newly-minted PhD candidate Olivia Pembridge on passing her PQE with flying colors today! Olivia will be using a wide array of iPSC and organoid models to study mechanisms of neurodevelopment!

094

Reposted by Andrew Stern

Young-Pearse Lab @typlab.bsky.social · 28/03/2025

If you're headed to #ADPD next week, be sure to stop by the TYP lab presentations by @gizemterzioglu.bsky.social and Zach Augur to learn about some of the amazing work the lab is doing!

182

Reposted by Andrew Stern

Young-Pearse Lab @typlab.bsky.social · 28/03/2025

Zach Augur will be presenting a poster during Shift 1 on April 2nd and 3rd titled "BAG3 IN ALZHEIMER’S DISEASE AND ITS IMPACT ON ASTROCYTE FUNCTION AND DISEASE PROGRESSION"

132

Reposted by Andrew Stern

Young-Pearse Lab @typlab.bsky.social · 28/03/2025

@gizemterzioglu.bsky.social will be presenting at the Microglia Symposium on the afternoon of April 4th! Her talk is titled "INPP5D/SHIP1 REGULATES MICROGLIA FUNCTION AND INFLAMMATORY RESPONSE IN ALZHEIMER'S DISEASE"

053

Andrew Stern @andrewmstern.bsky.social · 15/03/2025

Yes SEC followed by several techniques like ELISA, Western blot, EM, etc.

110

Andrew Stern @andrewmstern.bsky.social · 14/03/2025

It’s good to be skeptical! I agree - I don’t think there’s a distinct atomic structure of oligomers/protofibrils as distinct from fibrils found in plaques. But there are reasons “they” said these things.

000

Andrew Stern @andrewmstern.bsky.social · 14/03/2025

We’re still working on it! We have some interesting SEC data to share with you. I think Dennis or our postdoc Youqi will present some at AD/PD if you’ll be there (I won’t).

300

Andrew Stern @andrewmstern.bsky.social · 14/03/2025

In the case of Abeta, also from observations that aqueously extracted aggregates correlate with disease better than plaques do, but without structural information about those aggregates other than some antibody binding studies. Eg onlinelibrary.wiley.com/doi/abs/10.1...

onlinelibrary.wiley.com

Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

Genetic evidence strongly supports the view that Aβ amyloid production is central to the cause of Alzheimer's disease. The kinetics, compartmentation, and form of Aβ and its temporal relation to the ...

100

Reposted by Andrew Stern

Suzanne E. Schindler @suzanneeschindler.bsky.social · 05/03/2025

A very thoughtful and sobering piece by Dr. Jason Karlawish. "The problem is that the facts don't support Piller's message. It's sensational, and in my experience, it's causing harm." How a Book Is Undermining Progress Against Alzheimer's www.medpagetoday.com/opinion/seco...

141

Reposted by Andrew Stern

Jeremy Berg @jeremymberg.bsky.social · 05/03/2025

It was distressing to see the skepticism about Alzheimer's disease research expressed at the Bhattahcharya hearing today. This has been fueled by Charles Piller's sensationalized (NOT sensational) reporting and book. 1/n

2588

Reposted by Andrew Stern

Charles Jennings @chasjennings.bsky.social · 04/03/2025

Many Alzheimer’s researchers are also unhappy with Piller’s recent book and its negative characterization of the field, in which he inflates the significance of isolated fraud cases to argue that the entire field is corrupt. Here’s a rebuttal from my colleague Dennis Selkoe, published in STAT News:

statnews.com

There is no ‘amyloid cabal’ in Alzheimer’s research

“There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.”

0135

Reposted by Andrew Stern

Jeremy Berg @jeremymberg.bsky.social · 03/03/2025

@baldwin.senate.gov released a press release calling out the administration for damaging the Alzheimer's Disease Research Center network through it's screwing up NIH processes. www.baldwin.senate.gov/news/press-r... 1/2

baldwin.senate.gov

Baldwin Blasts Trump Administration for Stopping $65 Million for Alzheimer’s Disease Research | U.S. Senator Tammy Baldwin of Wisconsin

WASHINGTON, D.C. – Today, U.S. Senator Tammy Baldwin (D-WI), Ranking Member of the Senate...

412045

Reposted by Andrew Stern

Jeremy Berg @jeremymberg.bsky.social · 04/03/2025

If you want to learn about Charlie Piller's journalistic integrity, read this (long) thread. bsky.app/profile/jere... It is pretty telling...sensationalism without regard to getting the facts right.

2184